The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs by $7.3 billion over six years.
Cerebral, the fully comprehensive online mental health care provider, is proud to announce their new partnership with the San ...
Elisabeth Foley, a woman who lost her hand in a brutal shark attack, is no different. Although her medical team recommended the use of a prosthetic, her health insurance company did not deem it ...
CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
Self-funded Pennsylvania-based health plan Imagine360 is buying Ardent Health’s third-party administrator (TPA) HealthFirst, ...
Snyders Pharmacy, located in Oregon’s Ace Hardware, announced it has suspended operation of its drive-thru due to lack of ...
The Federal Trade Commission accuses CVS, Cigna and UnitedHealth of artificially inflating prices on specialty generic drugs ...
The markups helped the PBMs reap $7.3 billion from 2017 to 2022, the FTC found. The PBMs—owned by insurers Cigna, CVS Health and UnitedHealth Group—are supposed to help keep drug costs low for ...
Claro Advisors LLC lessened its stake in shares of The Cigna Group (NYSE:CI – Free Report) by 35.9% during the fourth quarter ...
The nation’s three largest PBMs – CVS Health’s Caremark, Cigna’s Express Scripts and UnitedHealth Group’s Optum Rx – inflated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback